Veradermics, Incorporated (MANE)
$116.26-5.02%Close
BUY
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $4.9B
- Beta
- 1.23
- P/E (TTM)
- -54.33
- Short % float
- 12.10%
- Days to cover
- 4.7
- SI change
- +3.4%
- 1W
- +6.70%
- 1M
- +14.32%
- vs SPY 1W
- +6.84%
- vs SPY 1M
- +11.81%
Industry peers
FMP comparable companies · ranked by market cap
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
FUNDAMENTALS
[SCORES & PROFILE]
- FUND
- 20
- VALUE
- 8
- GROWTH
- 47
- GARP
- 6
- TYPE
- Balanced
Composite of Value · Growth · GARP
ROIC-22.5%
REV YoY-
ROE-37.5%
EPS YoY-
ROA-11.2%
GROSS0
OP0
NET0
[VALUATION]
P/E TTM-54.33
P/E FWD-
SECTOR PE20.34
INDUSTRY PE13.84
P/B5.78
P/FCF-
EV/EBITDA-46.66
EV/EBIT-
PEG-
FCF YIELD-
RISK
INT COV-
D/E0.05
ALTMAN Z-
CURR RATIO70.53
ND/EBITDA-
BETA1.23
Company news
FAQ
- What is LOPJLB’s current signal on MANE?
- LOPJLB’s latest quantitative signal on Veradermics, Incorporated (MANE) is BUY. Signals are updated daily.
- What market regime is MANE in?
- LOPJLB classifies each ticker into BULL, RECOVERY, BEAR, or CRISIS regimes using a Hidden Markov Model.
- What does Veradermics, Incorporated (MANE) do?
- Veradermics, Incorporated functions as a biopharmaceutical enterprise focused on devising pioneering therapeutic interventions for various skin and cosmetic disorders. The company's development pipeline includes treatments for Pattern Hair Loss (PHL), impacting both adult and pediatric demographics. A flagship offering is VDPHL01, an orally administered, non-hormonal medication specifically for…